-
Overseas weight loss drug leader Novo Nordisk is expected to increase its annual operating profit by 40% to 46% at a constant exchange rate
Overseas weight loss drug leader Novo Nordisk is expected to increase its annual operating profit by 40% to 46% at a constant exchange rate.- Katlyn30590
- 2023-10-13
- サポート
- に反対
- 返信
- コレクション
-
New weight-loss drugs have become a market trend, and blue ocean pharmaceutical companies are rushing to expand their presence
On October 13th of this year, the stock price of American pharmaceutical giant Lilly reached a historic high of $629.97 per share. After three consecutive years of significant gains, Lilly became the ... -
GlobalData: In 2021, Lilly's weight loss drug Zepbound sold $4.1 billion in the United States
According to a recent report by data analysis company GlobalData, the newly approved weight loss drug Zepbound by American pharmaceutical company Eli Lilly will have sales of $4.1 billion in the Unit ...- qiu539790999
- 2023-11-13
- サポート
- に反対
- 返信
- コレクション
-
Novo Nordisk sues two pharmacies in the United States on suspicion of selling counterfeit weight loss pills
On November 30th local time, Novo Nordisk USA announced that as part of its ongoing commitment to patient safety, the company is taking several additional legal actions to protect American patients a ... -
Pfizer's failed development of oral weight loss drugs has no hope of turning around in the short term
The best performing companies in the healthcare sector this year have all benefited from the weight loss drug boom. Pfizer also hopes to make a comeback with an oral weight loss drug, but the latest ... -
Another pharmaceutical giant has entered the weight loss drug market! The GLP-1 track of the US stock market is once again hotly speculated
On Monday Eastern Time, Swiss pharmaceutical giant Roche announced its entry into the weight loss drug market through acquisition, challenging weight loss drug giants Novo Nordisk and Lilly. After th ... -
Lilly's weight loss pills were accused of rebounding after discontinuation, and the company's stock price plummeted at one point
According to the Red Star Capital Bureau, the stock price of weight loss drug giant LY. US fell at the beginning of trading on December 11th local time, with a drop of over 5% during the trading sess ... -
Overseas celebrity fund managers share next year's investment experience: Don't trust technology stocks, still be optimistic about weight loss pills!
An overseas star fund manager who outperformed 97% of his peers in performance this year shared his vision of next year's "investment experience" this week. One of the biggest highlights in his outlo ... -
Fake weight loss pills are rampant! Novo Nordisk is teaming up with Indian e-commerce platforms to vigorously curb illegal sales
According to a source, Novo Nordisk's legal team in India is collaborating with India's online e-commerce platform IndiaMART to develop a framework to remove counterfeit weight loss drugs from the pl ... -
Apple burst! Take down and stop selling! What happened? 3 trillion yuan giant's emergency crackdown on counterfeits is related to "weight loss pills"
Apple's sudden bearish news. On December 18th local time, Apple announced that starting from 3pm local time on December 21st, the official website of Apple in the United States will stop selling the ... -
The pharmaceutical landscape is completely overturned by 2023: in addition to weight loss drugs and hot money, they are also pouring into these fields
Throughout this year, major international pharmaceutical companies have made breakthroughs in multiple fields, which have not only benefited humanity but also changed the industry's landscape in the ... -
Weight loss pills will bring benefits again! FDA assessment: Wegovy and other drugs are not associated with suicidal thoughts
The latest discovery by US regulatory agencies that GLP-1 weight loss drugs such as Wegovy under Novo Nordisk are not associated with suicidal thoughts is a positive signal for these popular drugs an ... -
Over 1.8 billion yuan invested in the introduction of oral weight loss drugs, Novo Nordisk, to accelerate horse racing and compete in the weight loss market, upgrading the competition
Entering 2024, the track of weight loss pills remains hot. On January 23rd local time, Danish pharmaceutical giant Novo Nordisk and Swiss biotechnology company EraCal Therapeutics (hereinafter referr ... -
Weight loss drug giant Novo Nordisk's new move invests $11 billion to acquire a factory
Novo Nordisk announced a $11 billion acquisition of three production factories to meet the growing demand for weight loss drugs. On January 31st, Novo Nordisk released its 2023 results, with a total ... -
Novo Nordisk invests billions of dollars to buy factories and launches a battle for weight loss drug production capacity
Global weight loss drug leader Novo Nordisk has made new moves in expanding production. On February 5th, Novo Nordisk announced that its controlling shareholder Novo Holdings had agreed to acquire CD ... -
Are you optimistic about AI and weight loss pills? Qiaoshui Q4 significantly increases holdings of NVIDIA and Lilly
On Wednesday (February 14) Eastern Time, well-known hedge fund Bridgewater submitted its US stock holdings report (13F) as of the end of the fourth quarter of last year to the Securities and Exchange ... -
Has the "Seven Technology Giants" fallen out of favor? Xiaomo: Retail investors are turning to weight loss drug manufacturers such as Lilly
JPMorgan said in its latest report on Wednesday that retail investors sold most of the stocks in the "tech seven" last week, with the focus shifting to pharmaceutical companies such as Eli Lilly. Acc ... -
GLP-1 Weight Loss Drug Production Capacity Warming Up: Lilly builds a factory in Germany for $2.5 billion and is expected to operate in 2027
The GLP-1 weight loss drug, which is in a race for development, is also highly competitive in terms of production capacity. Recently, Lilly held a groundbreaking ceremony for a new factory in Frankfu ... -
Novo Nordisk promises to invest $6 billion to expand production capacity. Prices of weight loss drugs in the United States are expected to further decrease
On Thursday, weight loss drug giant Novo Nordisk held a earnings conference call, promising to further adopt a price reduction strategy in the US market. The company's Chief Financial Officer, Karste ... -
American pharmaceutical company Anjin's weight loss pills have attracted attention, and Novo Nordisk's stock price has fallen by 5%
American pharmaceutical company Anjin Weight Loss Medicine has attracted attention, with Novo Nordisk's stock price falling 5%.